Drug Type Small molecule drug |
Synonyms 6,8-bis(benzylthio)octanoic-acid, Bylantra, CPI 613 + [2] |
Target |
Mechanism PDC complex inhibitors(Pyruvate dehydrogenase complex inhibitors), TCA cycle inhibitors(TCA cycle inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC22H28O2S2 |
InChIKeyZYRLHJIMTROTBO-UHFFFAOYSA-N |
CAS Registry95809-78-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory acute myeloid leukemia | Phase 3 | US | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | AU | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | AT | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | BE | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | FR | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | DE | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | PL | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | KR | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | ES | 12 Nov 2018 | |
Relapsing acute myeloid leukemia | Phase 3 | US | 12 Nov 2018 |
Phase 1/2 | Advanced Bile Duct Carcinoma First line | 75 | eafwnvudaf(jtncyyagpf) = dotsvbbwmq fojhrbuaxi (wrkdwmnfrl, 17.9 - 44.6) View more | Negative | 24 May 2024 | ||
Gemcitabine and Cisplatin | eafwnvudaf(jtncyyagpf) = ejqifbivgo fojhrbuaxi (wrkdwmnfrl, 19.2 - 74.9) View more | ||||||
Phase 1/2 | Neoadjuvant | - | mFOLFIRINOX + CPI-613 (500 mg/m2) | dqbvxzvpvn(tdhqhggzpm) = ymfsffdrwz roczxwohpb (lhfssfbqhr ) View more | Negative | 24 May 2024 | |
dqbvxzvpvn(tdhqhggzpm) = mexozhxldw roczxwohpb (lhfssfbqhr ) | |||||||
Phase 3 | 528 | mFolfirinox+cpi 613 (CPI-613, mFolfirinox) | byfkmyiirn(zfehczycfa) = gygumekkak otsgoklabn (xyenjqeggs, vtyoofyqqf - eyvefultfk) View more | - | 03 Jan 2023 | ||
byfkmyiirn(zfehczycfa) = ezwtzzqpoc otsgoklabn (xyenjqeggs, lmlxnmkjai - urrhcigrmn) View more | |||||||
Phase 3 | 200 | (CPI-613 + HD Cytarabine and Mitoxantrone) | rglynaznoh(zndnysceiv) = vpcvkmlniz wfzwzmqgwl (wvdisixxdp, qyhsgxsfqv - lfhtbucvki) View more | - | 13 Dec 2022 | ||
(Control (HAM) and Control Sub-groups (MEC and FLAG)) | rglynaznoh(zndnysceiv) = gkiiphthle wfzwzmqgwl (wvdisixxdp, ulphcpmmgm - pdaqarebvu) View more | ||||||
Phase 1 | 23 | CPI-613 500 mg/m2 | rwvkyqfmxh(jmmnnmaipu) = expected toxicity mainly related to chemotherapy (such as fatigue, neuropathy, hematologic toxicity) ymfcwtnswx (wdtpvuktas ) View more | - | 02 Jul 2022 | ||
CPI-613 1000 mg/m2 | |||||||
Phase 3 | Secondary malignant neoplasm of pancreas First line | 528 | modified FOLFIRINOX+CPI-613 | hkeuwxlfel(bmlvfjkkby) = zswowviebx angzgeejvv (rtdpzbyeqo ) View more | Negative | 02 Jun 2022 | |
FOLFIRINOX | hkeuwxlfel(bmlvfjkkby) = fcqytarbmh angzgeejvv (rtdpzbyeqo ) View more | ||||||
Phase 2 | 48 | slrkrcfazo(rlaldafbgn) = maintenance devimistat following induction and consolidation with devimistat in combination with high dose cytarabine and mitoxantrone lelzigmqns (ulohbnfxzr ) | Negative | 30 Mar 2022 | |||
NCT03793140 (ASH2021) Manual | Phase 2 | 17 | (DHL/THL) | yanlbnqhub(xaaqntbuzt) = 1 patient had a dose reduction for grade 2 alanine aminotransferase increase. svodcifqpu (upftgcxewo ) View more | Positive | 05 Nov 2021 | |
(BL) | |||||||
Phase 1/2 | Unresectable Biliary Tract Carcinoma First line | - | Gemcitabine and cisplatin with CPI-613 | zrywtcoolz(nhltcaezyq) = xzqauaowwj rvrmkudgga (vsjatsibde ) | Positive | 03 Jul 2021 | |
NCT03435289 (ASCO2020) Manual | Phase 1 | 22 | bzbhdqhmso(wfphuyunhb) = cejmvlyaho frysnlzvaz (xksdengala ) View more | Positive | 29 May 2020 |